MoU between C-CAMP and IHMA to combat Antimicrobal Resistance

Centre for Cellular and Molecular Platforms (C-CAMP) has signed a Memorandum of Understanding (MoU) with International Health Management Associates (IHMA).

C-CAMP and IHMA will jointly facilitate microbiology-related studies for clinical trials, surveillance studies, mentorship programmes and other activities to market new drug and vaccine discovery within the area of anti-infectives and new-age diagnostic device development to deal with AMR.

Now IHMA with its advanced microbiology lab is supporting anti-infective and diagnostic development studies for over 25 years has laboratory facilities within the US, Switzerland and China plus a office in India. C-CAMP is currently performing on solutions against AMR through its AMR Accelerator programme that was launched in 2020.

“AMR is widely acknowledged because the biggest threat to 21st century medicine. As innovators across the planet race to develop next generation antimicrobials and vaccines, it’s crucial that the regulatory and commercial routes to success for these paths are smooth and obstacle-free. We are delighted to announce that this MoU with IHMA will bring a world-class 360-degree service model to Indian innovators within the drug discovery arena along side exposure to global regulatory standards,” said Dr Taslimarif Saiyed, C-CAMP’s CEO and director.

The Bengaluru-based C-CAMP is positioned as India’s premier bio research & innovation hub with a portfolio cover the whole life sciences spectrum. Its AMR programmes are designed to spot and accelerate commercialization of innovations. Its analytical and technology platforms are accessible to researchers during a service mode. Further, C-CAMP’s marquee start-ups like Bugworks have risen to international prominence with an exciting pipeline of next generation broad-spectrum antimicrobials. C-CAMP is additionally a member of the CARB-X Global Accelerator Network, a league of 10 top organizations combating AMR across USA and Europe.

IHMA features a diverse library of clinically relevant phenotypically and genotypically characterized bacterial and fungal isolates which will be wont to assist with profiling of anti-infective agents during development.

Dr Darcie Carpenter, director, global business development, IHMA welcoming the MoU said “The IHMA Team is extremely excited about collaborating with C-CAMP. This MoU with C-CAMP will help provide additional support to Indian innovators to make subsequent generation antibiotics to fight AMR.”